U.S., June 19 -- ClinicalTrials.gov registry received information related to the study (NCT07026539) titled 'Effect of Treatment With Finerenone on Cardio-Renal Target Organ Damage in Patients With Type 2 Diabetes - A Randomized Trial' on June 10.
Brief Summary: The global prevalence of diabetes is increasing substantially. Around 40 % of patients with type 2 diabetes develop chronic kidney disease. Diabetic kidney disease is the leading cause of kidney failure, it is closely linked to cardiovascular disease and heart failure and is associated with a threefold increase in all-cause mortality and a 16-year loss in life expectancy.
In large clinical trials, the novel drug finerenone has shown to lower the risk of chronic kidney disease prog...